Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
This study has been terminated.
(Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease progression.)
Information provided by:
First received: June 2, 2003
Last updated: August 10, 2007
Last verified: August 2007
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
Carcinoma, Non-Small-Cell Lung
Drug: ABT-510/Thrombospondin-1 mimetic
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Primary Outcome Measures:
- Progression free survival [ Time Frame: One year ]
Secondary Outcome Measures:
- Overall survival [ Time Frame: One year ]
- Response rate [ Time Frame: One year ]
| Study Start Date:
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- The subject has a history of or currently exhibits Central Nervous System (CNS) metastasis. Brain MRI within 28 days of enrollment is required to confirm absence of CNS metastases.
- The subject is receiving therapeutic anticoagulation therapy. Low dose anticoagulation for catheter prophylaxis will be permitted; PT/PTT must be within normal limits.
- The subject has a history of or currently exhibits clinically significant cancer related events of bleeding (e.g., hemoptysis). The subject has a recent history of (within 4 weeks from Study Day 1) or currently exhibits other clinically significant events of bleeding.
- The subject has received investigational therapy within four weeks prior to study drug administration.
- The subject exhibits evidence of clinically significant uncontrolled condition(s) and/or is considered by the investigator to be unable to tolerate the proposed treatment or procedures.
- The subject has previous or current malignancies at other sites, with the exception of: Adequately treated in situ carcinoma of the cervix uteri; Basal or squamous cell carcinoma of the skin; Previous nonpulmonary malignancy confined and surgically resected with no evidence of active malignancy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00061646
|Oncology-Hematology Group of South Florida
|Miami, Florida, United States, 33176 |
|University of Chicago
|Chicago, Illinois, United States, 60637-1470 |
|The West Cancer Clinic
|Memphis, Tennessee, United States, 38120 |
|University of Wisconsin
|Madison,, Wisconsin, United States, 53792-5666 |
||Global Medical Information 1-800-633-9110
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 2, 2003
||August 10, 2007
||United States: Food and Drug Administration
Keywords provided by Abbott:
Stage IIIb with pleural effusion or IV NSCLC
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 18, 2014
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases